Asrar Alam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Asrar Alam has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Ashekul Islam
Department of Biochemistry and Molecular Biology Mawlana Bhashani Science and Technology University Tangail Bangladesh
2 shared publications Daisuke S. Yamamoto
Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical University, Shimotsuke, Japan
2 shared publications- Fitri Amelia
Laboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa University, Kanazawa, Japan
2 shared publications - Mohammad Azam Ansari
Department of Epidemic Disease Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia
2 shared publications Raj K. Bhatnagar
2 shared publications- Shigeto Yoshida
Laboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa, Japan
2 shared publications
Latest Publications
- 25 June 2023
- Published by Springer Nature
- p. 179-195
Role of Biomarkers in Cancer Prevention and Therapy
- 25 June 2023
- Published by Springer Nature
- p. 179-195
Role of Biomarkers in Cancer Prevention and Therapy
- 3 March 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (14) , 1793-1810
Molecular Approaches to Lung Cancer Prevention
Lung cancer is generally diagnosed at advanced stages when surgical resection is not possible. Late diagnosis, along with development of chemoresistance, results in high mortality. Preventive appro...
- 3 March 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (14) , 1793-1810
Molecular Approaches to Lung Cancer Prevention
Lung cancer is generally diagnosed at advanced stages when surgical resection is not possible. Late diagnosis, along with development of chemoresistance, results in high mortality. Preventive appro...
- 24 April 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (11) , 1138-1144
Recent Nano-based Therapeutic Intervention of Bioactive Sesquiterpenes: Prospects in Cancer Therapeutics
: In the recent scenario, nanotechnology-based therapeutics intervention has gained tremendous impetus all across the globe. Nano-based pharmacological intervention of various bioactive compounds has been explored on an increasing scale. Sesquiterpenes are major constituents of essential oils (EOs) present in various plant species which possess intriguing therapeutic potentials. However, owing to their poor physicochemical properties; they have pharmacological limitations. Recent advances in nano-based therapeutic interventions offer various avenues to improve their therapeutic applicability. Reckoning with these, the present review collates various nano-based therapeutic intervention of sesquiterpenes with prospective potential against various debilitating diseases especially cancer. In our viewpoint, considering the burgeoning advancement in the field of nanomedicine; in the near future, the clinical applicability of these nano-formulated sesquiterpenes can be foreseen with great enthusiasm.
- 24 April 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (11) , 1138-1144
Recent Nano-based Therapeutic Intervention of Bioactive Sesquiterpenes: Prospects in Cancer Therapeutics
: In the recent scenario, nanotechnology-based therapeutics intervention has gained tremendous impetus all across the globe. Nano-based pharmacological intervention of various bioactive compounds has been explored on an increasing scale. Sesquiterpenes are major constituents of essential oils (EOs) present in various plant species which possess intriguing therapeutic potentials. However, owing to their poor physicochemical properties; they have pharmacological limitations. Recent advances in nano-based therapeutic interventions offer various avenues to improve their therapeutic applicability. Reckoning with these, the present review collates various nano-based therapeutic intervention of sesquiterpenes with prospective potential against various debilitating diseases especially cancer. In our viewpoint, considering the burgeoning advancement in the field of nanomedicine; in the near future, the clinical applicability of these nano-formulated sesquiterpenes can be foreseen with great enthusiasm.
- Open Access
- 5 April 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 730
Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming
An ideal malaria vaccine platform should potently induce protective immune responses and block parasite transmission from mosquito to human, and it should maintain these effects for an extended period. Here, we have focused on vaccine development based on adeno-associated virus serotype 1 (AAV1), a viral vector widely studied in the field of clinical gene therapy that is able to induce long-term transgene expression without causing toxicity in vivo. Our results show the potential utility of AAV1 vectors as an extremely potent booster vaccine to induce durable immunity when combined with an adenovirus-priming vaccine in a rodent malaria model. We generated a series of recombinant AAV1s and human adenovirus type 5 (AdHu5) expressing either Plasmodium falciparum circumsporozoite protein (PfCSP) or P25 (Pfs25) protein. Heterologous two-dose immunization with an AdHu5-prime and AAV1-boost (AdHu5-AAV1) elicited robust and durable PfCSP- or Pfs25-specific functional antibodies over 280 days. Regarding protective efficacy, AdHu5-AAV1 PfCSP achieved high sterile protection (up to 80% protection rate) against challenge with transgenic Plasmodium berghei sporozoites expressing PfCSP. When examining transmission-blocking (TB) efficacy, we found that immunization with AdHu5-AAV1 Pfs25 maintained TB activity in vivo against transgenic P. berghei expressing Pfs25 for 287 days (99% reduction in oocyst intensity, 85% reduction in oocyst prevalence). Our data indicate that AAV1-based malaria vaccines can confer potent and durable protection as well as TB efficacy when administered following an AdHu5 priming vaccine, supporting the further evaluation of this regimen in clinical trials as a next-generation malaria vaccine platform.
- 5 April 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 730
Open AccessAdeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming
An ideal malaria vaccine platform should potently induce protective immune responses and block parasite transmission from mosquito to human, and it should maintain these effects for an extended period. Here, we have focused on vaccine development based on adeno-associated virus serotype 1 (AAV1), a viral vector widely studied in the field of clinical gene therapy that is able to induce long-term transgene expression without causing toxicity in vivo. Our results show the potential utility of AAV1 vectors as an extremely potent booster vaccine to induce durable immunity when combined with an adenovirus-priming vaccine in a rodent malaria model. We generated a series of recombinant AAV1s and human adenovirus type 5 (AdHu5) expressing either Plasmodium falciparum circumsporozoite protein (PfCSP) or P25 (Pfs25) protein. Heterologous two-dose immunization with an AdHu5-prime and AAV1-boost (AdHu5-AAV1) elicited robust and durable PfCSP- or Pfs25-specific functional antibodies over 280 days. Regarding protective efficacy, AdHu5-AAV1 PfCSP achieved high sterile protection (up to 80% protection rate) against challenge with transgenic Plasmodium berghei sporozoites expressing PfCSP. When examining transmission-blocking (TB) efficacy, we found that immunization with AdHu5-AAV1 Pfs25 maintained TB activity in vivo against transgenic P. berghei expressing Pfs25 for 287 days (99% reduction in oocyst intensity, 85% reduction in oocyst prevalence). Our data indicate that AAV1-based malaria vaccines can confer potent and durable protection as well as TB efficacy when administered following an AdHu5 priming vaccine, supporting the further evaluation of this regimen in clinical trials as a next-generation malaria vaccine platform.
- 15 October 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 201 (8) , 2441-2451
Baculovirus-Induced Fast-Acting Innate Immunity Kills Liver-Stage Plasmodium
Baculovirus (BV), an enveloped insect virus with a circular dsDNA genome, possesses unique characteristics that induce strong innate immune responses in mammalian cells. In this study, we show that BV administration in BALB/c mice not only provides complete protection against a subsequent Plasmodium berghei sporozoite infection for up to 7 d after the injection but also eliminates existing liver-stage parasites completely. The elimination of sporozoites by BV was superior to that by primaquine, and this effect occurred in a TLR9-independent manner. At 6 h after BV administration, IFN-α and IFN-γ were robustly produced in the serum, and RNA transcripts of IFN-stimulated genes were markedly upregulated in the liver compared with control mice. The in vivo passive transfer of serum after BV administration effectively eliminated liver-stage parasites, and IFN-α neutralization abolished this effect, indicating that the BV liver-stage parasite-killing mechanism is downstream of the type I IFN signaling pathway. These findings provide evidence that BV-induced, fast-acting innate immunity completely kills liver-stage parasites and, thus, may lead to new malaria drug and vaccine strategies.
- 15 October 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 201 (8) , 2441-2451
Baculovirus-Induced Fast-Acting Innate Immunity Kills Liver-Stage Plasmodium
Baculovirus (BV), an enveloped insect virus with a circular dsDNA genome, possesses unique characteristics that induce strong innate immune responses in mammalian cells. In this study, we show that BV administration in BALB/c mice not only provides complete protection against a subsequent Plasmodium berghei sporozoite infection for up to 7 d after the injection but also eliminates existing liver-stage parasites completely. The elimination of sporozoites by BV was superior to that by primaquine, and this effect occurred in a TLR9-independent manner. At 6 h after BV administration, IFN-α and IFN-γ were robustly produced in the serum, and RNA transcripts of IFN-stimulated genes were markedly upregulated in the liver compared with control mice. The in vivo passive transfer of serum after BV administration effectively eliminated liver-stage parasites, and IFN-α neutralization abolished this effect, indicating that the BV liver-stage parasite-killing mechanism is downstream of the type I IFN signaling pathway. These findings provide evidence that BV-induced, fast-acting innate immunity completely kills liver-stage parasites and, thus, may lead to new malaria drug and vaccine strategies.
- 30 July 2015
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 12 (8) , 673-679
In silico Analysis of Plasmodium falciparum Actin and Profilin Interaction at the Interface Region for Antimalarial Drug Designing
Malaria parasite Plasmodium falciparum actively invades its host cells utilizing its actin/ myosin-based motor machinery. Actin-profilin interaction is essential for actin filament dynamics in eukaryotic cells. P.falciparum profilin (PfPRF) is highly divergent from other eukaryotic profilins and possesses unique structural properties. In this study, we attempted to identify region(s) of P.falciparum actins (PfACT1 and PfACT2) that interact with unique region(s) of PfPRF at the binding interface. We identified nine-residue peptides from PfACT1 (PLNPKGNRE) and PfACT2 (PLNPKTNRE) that interacted with a unique region of PfPRF. This interaction was largely absent from docked human beta actin-human profilin 1 complex. By molecular docking, the peptide derived from PfACT1 bound at the unique region of the PfPRF interface. Virtual screening based on the peptide-binding region of PfPRF identified a number of drug-like molecules. Our study demonstrated that the unique region of PfPRF could be specifically targeted. Since actin polymerization is essential for parasite motility and invasion, inhibitors specifically targeting parasite actin-profilin interaction could be potential antimalarials.
- 30 July 2015
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 12 (8) , 673-679
In silico Analysis of Plasmodium falciparum Actin and Profilin Interaction at the Interface Region for Antimalarial Drug Designing
Malaria parasite Plasmodium falciparum actively invades its host cells utilizing its actin/ myosin-based motor machinery. Actin-profilin interaction is essential for actin filament dynamics in eukaryotic cells. P.falciparum profilin (PfPRF) is highly divergent from other eukaryotic profilins and possesses unique structural properties. In this study, we attempted to identify region(s) of P.falciparum actins (PfACT1 and PfACT2) that interact with unique region(s) of PfPRF at the binding interface. We identified nine-residue peptides from PfACT1 (PLNPKGNRE) and PfACT2 (PLNPKTNRE) that interacted with a unique region of PfPRF. This interaction was largely absent from docked human beta actin-human profilin 1 complex. By molecular docking, the peptide derived from PfACT1 bound at the unique region of the PfPRF interface. Virtual screening based on the peptide-binding region of PfPRF identified a number of drug-like molecules. Our study demonstrated that the unique region of PfPRF could be specifically targeted. Since actin polymerization is essential for parasite motility and invasion, inhibitors specifically targeting parasite actin-profilin interaction could be potential antimalarials.
- Open Access
- 18 December 2014
- Published by Wiley in Malaria Research and Treatment
- Vol. 2014, 1-8
Bioinformatic Identification of Peptidomimetic-Based Inhibitors againstPlasmodium falciparumAntigen AMA1
Plasmodium falciparumapical membrane antigen 1 (PfAMA1) is a valuable vaccine candidate and exported on the merozoite surface at the time of erythrocyte invasion. PfAMA1 interacts with rhoptry neck protein PfRON2, a component of the rhoptry protein complex, which forms the tight junction at the time of invasion. Phage display studies have identified a 15-residue (F1) and a 20-residue (R1) peptide that bind to PfAMA1 and block the invasion of erythrocytes. Cocrystal structures of central region of PfAMA1 containing disulfide-linked clusters (domains I and II) with R1 peptide and a peptide derived from PfRON2 showed strong structural similarity in binding. The peptides bound to a hydrophobic groove surrounded by domain I and II loops. In this study, peptidomimetics based on the crucial PfAMA1-binding residues of PfRON2 peptide have been identified. Top 5 peptidomimetics when checked for their docking on the region of PfAMA1 encompassing the hydrophobic groove were found to dock on the groove. Drug-like molecules having structural similarity to the top 5 peptidomimetics were identified based on their binding ability to PfAMA1 hydrophobic groove in blind docking. These inhibitors provide potential lead compounds, which could be used in the development of antimalarials targeting PfAMA1.
- 18 December 2014
- Published by Wiley in Malaria Research and Treatment
- Vol. 2014, 1-8
Open AccessBioinformatic Identification of Peptidomimetic-Based Inhibitors againstPlasmodium falciparumAntigen AMA1
Plasmodium falciparumapical membrane antigen 1 (PfAMA1) is a valuable vaccine candidate and exported on the merozoite surface at the time of erythrocyte invasion. PfAMA1 interacts with rhoptry neck protein PfRON2, a component of the rhoptry protein complex, which forms the tight junction at the time of invasion. Phage display studies have identified a 15-residue (F1) and a 20-residue (R1) peptide that bind to PfAMA1 and block the invasion of erythrocytes. Cocrystal structures of central region of PfAMA1 containing disulfide-linked clusters (domains I and II) with R1 peptide and a peptide derived from PfRON2 showed strong structural similarity in binding. The peptides bound to a hydrophobic groove surrounded by domain I and II loops. In this study, peptidomimetics based on the crucial PfAMA1-binding residues of PfRON2 peptide have been identified. Top 5 peptidomimetics when checked for their docking on the region of PfAMA1 encompassing the hydrophobic groove were found to dock on the groove. Drug-like molecules having structural similarity to the top 5 peptidomimetics were identified based on their binding ability to PfAMA1 hydrophobic groove in blind docking. These inhibitors provide potential lead compounds, which could be used in the development of antimalarials targeting PfAMA1.
- Open Access
- 17 December 2014
- Published by Wiley in Malaria Research and Treatment
- Vol. 2014, 1-13
Exploiting Unique Structural and Functional Properties of Malarial Glycolytic Enzymes for Antimalarial Drug Development
Metabolic enzymes have been known to carry out a variety of functions besides their normal housekeeping roles known as “moonlighting functions.” These functionalities arise from structural changes induced by posttranslational modifications and/or binding of interacting proteins. Glycolysis is the sole source of energy generation for malaria parasitePlasmodium falciparum, hence a potential pathway for therapeutic intervention. Crystal structures of severalP. falciparumglycolytic enzymes have been solved, revealing that they exhibit unique structural differences from the respective host enzymes, which could be exploited for their selective targeting. In addition, these enzymes carry out many parasite-specific functions, which could be of potential interest to control parasite development and transmission. This review focuses on the moonlighting functions ofP. falciparumglycolytic enzymes and unique structural differences and functional features of the parasite enzymes, which could be exploited for therapeutic and transmission blocking interventions against malaria.
- 17 December 2014
- Published by Wiley in Malaria Research and Treatment
- Vol. 2014, 1-13
Open AccessExploiting Unique Structural and Functional Properties of Malarial Glycolytic Enzymes for Antimalarial Drug Development
Metabolic enzymes have been known to carry out a variety of functions besides their normal housekeeping roles known as “moonlighting functions.” These functionalities arise from structural changes induced by posttranslational modifications and/or binding of interacting proteins. Glycolysis is the sole source of energy generation for malaria parasitePlasmodium falciparum, hence a potential pathway for therapeutic intervention. Crystal structures of severalP. falciparumglycolytic enzymes have been solved, revealing that they exhibit unique structural differences from the respective host enzymes, which could be exploited for their selective targeting. In addition, these enzymes carry out many parasite-specific functions, which could be of potential interest to control parasite development and transmission. This review focuses on the moonlighting functions ofP. falciparumglycolytic enzymes and unique structural differences and functional features of the parasite enzymes, which could be exploited for therapeutic and transmission blocking interventions against malaria.
- Open Access
- 11 March 2014
- Published by Wiley in Interdisciplinary Perspectives on Infectious Diseases
- Vol. 2014, 1-7
Serine Proteases of Malaria ParasitePlasmodium falciparum: Potential as Antimalarial Drug Targets
Malaria is a major global parasitic disease and a cause of enormous mortality and morbidity. Widespread drug resistance against currently available antimalarials warrants the identification of novel drug targets and development of new drugs. Malarial proteases are a group of molecules that serve as potential drug targets because of their essentiality for parasite life cycle stages and feasibility of designing specific inhibitors against them. Proteases belonging to various mechanistic classes are found inP. falciparum, of which serine proteases are of particular interest due to their involvement in parasite-specific processes of egress and invasion. InP. falciparum, a number of serine proteases belonging to chymotrypsin, subtilisin, and rhomboid clans are found. This review focuses on the potential ofP. falciparumserine proteases as antimalarial drug targets.
- 11 March 2014
- Published by Wiley in Interdisciplinary Perspectives on Infectious Diseases
- Vol. 2014, 1-7
Open AccessSerine Proteases of Malaria ParasitePlasmodium falciparum: Potential as Antimalarial Drug Targets
Malaria is a major global parasitic disease and a cause of enormous mortality and morbidity. Widespread drug resistance against currently available antimalarials warrants the identification of novel drug targets and development of new drugs. Malarial proteases are a group of molecules that serve as potential drug targets because of their essentiality for parasite life cycle stages and feasibility of designing specific inhibitors against them. Proteases belonging to various mechanistic classes are found inP. falciparum, of which serine proteases are of particular interest due to their involvement in parasite-specific processes of egress and invasion. InP. falciparum, a number of serine proteases belonging to chymotrypsin, subtilisin, and rhomboid clans are found. This review focuses on the potential ofP. falciparumserine proteases as antimalarial drug targets.